Document is current
Any future updates will be listed below
-
Authors
Park, Junsik https://orcid.org/0000-0003-4094-2097
Kim, Jung Chul
Lee, Miran
Lee, JooHyang
Kim, Yoo-Na
Lee, Yong Jae
Kim, Sunghoon
Kim, Sang Wun
Park, Su-Hyung
Lee, Jung-Yun https://orcid.org/0000-0001-7948-1350
-
Funding
Funding for this research was provided by:
Yonsei University | Yonsei University College of Medicine (6-2021-0115)
National Research Foundation of the Republic of Korea
- License Information
-
More Information
Article History
Received: 16 January 2023
Revised: 13 September 2023
Accepted: 26 September 2023
First Online: 11 October 2023
Competing interests
: J-YL reports grants and personal fees from Beigene, Bergenbio, Clovis Oncology, Immunogen, Janssen, Merck, MSD, Novartis, Roche, Seagen, Synthon, and Takeda. All other authors have no conflicts of interest to disclose.
: This study was approved by the Institutional Review Board of Yonsei College of Medicine (cohort 1: 4-2018-0342 and 4-2022-1170; cohort 2: 4-2020-0386). All enrolled patients agreed to participate in the study by providing informed consent. This study was conducted in accordance with the Declaration of Helsinki.
